CD34 and neoplasm: Thus, it is often difficult to standardize and scale up the precise conditions, such as the DC source (monocytes, CD34+ precursors or other subsets), the composition of the maturation cocktail, the nature of the tumor antigen (TAA or tissue-specific antigens), and the route and dose of DC vaccination [55].